KTRA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients...

Stats
Today's Volume	7.11M
Average Volume	13.84M
Market Cap	6.71M
EPS	$0 ( 2024-02-13 )
Next earnings date	( $-0.250 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-30	Johnson Laura L.	Buy	8 500	Options (Right to Buy)
2023-08-30	Favorito Tamara A	Buy	8 500	Options (Right to Buy)
2023-08-30	Hoffman Robert E.	Buy	23 142	Options (Right to Buy)
2023-08-30	Toth Robert Joseph Jr	Buy	8 500	Options (Right to Buy)
2023-08-30	Brown Dennis M	Buy	10 175	Options (Right to Buy)

INSIDER POWER
100.00
Last 96 transactions
Buy: 12 848 509 \| Sell: 15 566

Volume Correlation

Long: -0.13 (neutral)

Short: -0.96 (very strong negative)

Signal:(51.138) Neutral

Kintara Therapeutics, Correlation

10 Most Positive Correlations
CRON	0.925
EVLO	0.918
RPTX	0.904
SLNG	0.901
CFRX	0.899
DRUG	0.898
LVTX	0.897
JAGX	0.895
REYN	0.894
KNSA	0.894

10 Most Negative Correlations
CSLM	-0.923
HERA	-0.911
TBSAU	-0.91
CITE	-0.909
PPYA	-0.906
HERAU	-0.903
FRON	-0.903
ABGI	-0.903
FTAA	-0.901
BYNOU	-0.901

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kintara Therapeutics, Correlation - Currency/Commodity

0.00
( neutral )

0.13
( neutral )

Kintara Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-60 000.00 (0.00 %)
EPS:	$-9.04

Q4	2023
Revenue:	$0
Gross Profit:	$-15 000.00 (0.00 %)
EPS:	$-1.970

Q3	2023
Revenue:	$0
Gross Profit:	$-15 000.00 (0.00 %)
EPS:	$-1.920

Q2	2023
Revenue:	$0
Gross Profit:	$-15 000.00 (0.00 %)
EPS:	$-2.07

Financial Reports:

No articles found.

Kintara Therapeutics,

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.